GlassScriptPhysician profile
Scott Simeon
NPI 1093784696
$19,493.42
in general payments reported to CMS, 2019-2025
42 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,987 · 2020: $2,430 · 2021: $2,855 · 2022: $2,958 · 2023: $3,318 · 2024: $2,587 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,263.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,125.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,633.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $2,388.48 | 2019-2025 | |
| Novo Nordisk INC | $2,215.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,354.17 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Abbvie INC. | $1,259.06 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,214.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $805.06 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $361.42 | 2019-2023 | Austedo Xr |
| Amgen INC. | $359.13 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $358.73 | 2019-2025 | Belsomra, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $337.28 | 2019-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $296.76 | 2022 | |
| Exact Sciences Corporation | $292.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $273.45 | 2020-2023 | Xarelto |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Simeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.